Market Cap | 91.82M | P/E | - | EPS this Y | - | Ern Qtrly Grth | - |
Income | -59.08M | Forward P/E | -1.33 | EPS next Y | - | 50D Avg Chg | -26.00% |
Sales | - | PEG | - | EPS past 5Y | - | 200D Avg Chg | -7.00% |
Dividend | N/A | Price/Book | N/A | EPS next 5Y | 34.40% | 52W High Chg | -40.00% |
Recommedations | 3.00 | Quick Ratio | 3.68 | Shares Outstanding | 54.39M | 52W Low Chg | 84.00% |
Insider Own | 25.20% | ROA | -83.63% | Shares Float | 41.94M | Beta | 2.17 |
Inst Own | 19.46% | ROE | - | Shares Shorted/Prior | 2.66M/2.80M | Price | 2.14 |
Gross Margin | - | Profit Margin | - | Avg. Volume | 760,909 | Target Price | 0.50 |
Oper. Margin | - | Earnings Date | May 9 | Volume | 1,451,657 | Change | -5.73% |
Galera Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the transformation of radiotherapy in cancer. The company's lead product candidate is avasopasem manganese (GC4419), a small molecule dismutase mimetic, which has completed Phase III clinical trial for the treatment of radiotherapy induced severe oral mucositis in patients with head and neck cancer (HNC); in Phase IIa clinical trial for the treatment of radiotherapy-induced esophagitis in patients with lung cancer; and in Phase IIa clinical trial for patients with HNC undergoing standard-of-care radiotherapy. It is also developing GC4711, a dismutase mimetic product candidate, which is in Phase I/II clinical trial in combination with stereotactic body radiation therapy in patients with non-small cell lung cancer and locally advanced pancreatic cancer. The company was incorporated in 2012 and is based in Malvern, Pennsylvania.
Citigroup | Neutral | Aug 29, 23 |
HC Wainwright & Co. | Neutral | Aug 16, 23 |
Piper Sandler | Neutral | Aug 10, 23 |
HC Wainwright & Co. | Buy | Jul 17, 23 |
HC Wainwright & Co. | Buy | Mar 22, 23 |
Piper Sandler | Overweight | Feb 21, 23 |
B of A Securities | Buy | Feb 16, 23 |
HC Wainwright & Co. | Buy | Feb 16, 23 |
B of A Securities | Underperform | May 27, 22 |
Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
---|---|---|---|---|---|---|---|---|
Sorensen Mel | President and CEO President and CEO | Mar 10 | Buy | 1.6812 | 100,000 | 168,120 | 332,044 | 03/14/23 |
Degnan Chris | Chief Financial Offi.. Chief Financial Officer | Mar 13 | Buy | 1.9593 | 10,000 | 19,593 | 10,000 | 03/14/23 |